Sentinel node evaluation in prostate cancer.

Authors

Ramkishen Narayanan, John Wayne Cancer Institute at Providence Saint John's Health Center, 2200 Santa Monica Blvd, Suite 131, Santa Monica, CA, 90404, USAFollow
Timothy G Wilson, John Wayne Cancer Institute at Providence Saint John's Health Center, 2200 Santa Monica Blvd, Suite 131, Santa Monica, CA, 90404, USA

Document Type

Article

Publication Date

8-1-2018

Keywords

Lymph node invasion; Lymph node metastasis(es); Lymph node(s); Pelvic lymph node dissection (or pelvic lymphadenectomy); Prostate cancer; Sentinel lymph node biopsy; Sentinel lymph node dissection; Sentinel lymph node(s)

Abstract

Sentinel lymph node (SLN) based pelvic lymph node dissection (PLND) in prostate cancer (PCa) is appealing over the time, cost and morbidity classically attributed to conventional PLND during radical prostatectomy. The initial report of feasibility of the SLN concept in prostate cancer was nearly 20 years ago. However, PLND based on the SLN concept, either SLN biopsy of a single node or targeted SLN dissection of multiple nodes, is still considered investigational in PCa. To better appreciate the challenges, and potential solutions, associated with SLN-based PLND in PCa, this review will discuss the rationale behind PLND in PCa and evaluate current SLN efforts in the most commonly diagnosed malignancy in men in the US.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology